company background image
600671 logo

Hangzhou TianMuShan Pharmaceutical EnterpriseLtd SHSE:600671 Stock Report

Last Price

CN¥8.78

Market Cap

CN¥1.1b

7D

4.4%

1Y

15.5%

Updated

01 May, 2024

Data

Company Financials

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

SHSE:600671 Stock Report

Market Cap: CN¥1.1b

600671 Stock Overview

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China.

600671 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Risk Analysis


Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hangzhou TianMuShan Pharmaceutical EnterpriseLtd
Historical stock prices
Current Share PriceCN¥8.78
52 Week HighCN¥12.41
52 Week LowCN¥7.21
Beta0.32
1 Month Change-3.83%
3 Month Change-17.94%
1 Year Change15.53%
3 Year Change3.91%
5 Year Change-42.58%
Change since IPO159.09%

Recent News & Updates

Recent updates

Shareholder Returns

600671CN PharmaceuticalsCN Market
7D4.4%5.7%4.2%
1Y15.5%-11.0%-13.2%

Return vs Industry: 600671 exceeded the CN Pharmaceuticals industry which returned -11% over the past year.

Return vs Market: 600671 exceeded the CN Market which returned -13.2% over the past year.

Price Volatility

Is 600671's price volatile compared to industry and market?
600671 volatility
600671 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement7.7%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 600671's share price has been volatile over the past 3 months.

Volatility Over Time: 600671's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1958371Bo Liuwww.hztmyy.com

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, granules, and other health foods. It is also involved in the sale of menthol and peppermint oil raw materials, Chinese medicine formulas, Chinese medicine pieces, fresh herbs, etc.; and provision of professional medical services, such as valet decoction and distribution, as well as Chinese medicine diagnosis and treatment services.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Fundamentals Summary

How do Hangzhou TianMuShan Pharmaceutical EnterpriseLtd's earnings and revenue compare to its market cap?
600671 fundamental statistics
Market capCN¥1.07b
Earnings (TTM)-CN¥38.94m
Revenue (TTM)CN¥137.86m

7.8x

P/S Ratio

-27.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600671 income statement (TTM)
RevenueCN¥137.86m
Cost of RevenueCN¥107.46m
Gross ProfitCN¥30.39m
Other ExpensesCN¥69.34m
Earnings-CN¥38.94m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin22.05%
Net Profit Margin-28.25%
Debt/Equity Ratio166.6%

How did 600671 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.